The Influence of the Pretreatment Host Immune Inflammatory State and Response to Radiation Therapy in High Risk Adenocarcinoma of the Prostate: A Validation Study from NRG Oncology/RTOG 0521

ALBA M GÜERCI

CABA

Congreso; IV Best of ASTRO en Argentina; 2019

SATRO. SOCIEDAD ARGENTINA DE TERAPIA RADIANTE ONCOLOGICA

The host immuno-inflammatory state, as reflected by elevation in C-Reactive Protein (CRP), has been shown to be associated with poor outcomes following radiation therapy (RT)Cytokine modulators of the immuno-inflammatory response, such as IL-10, have been shown to be associated with oncologic progressionWe hypothesized there could be an interaction between the pre-treatment host immune state and response to radiation therapy We conducted a validation study using prospectively banked serum specimens from the phase III clinical trial RTOG 0521 which evaluated the addition of docetaxel to androgen suppression and RT for high risk prostate cancer